Last updated on August 2018

A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis


Brief description of study

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous injection weekly for 13 weeks.

The study consists of 2 parts. Part 1, the Phase 1b, is an open-label multiple dose escalation study to evaluate the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. Part 2, the Phase 2, is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KZR-616 in patients with active proliferative lupus nephritis (LN).

Clinical Study Identifier: NCT03393013

Contact Investigators or Research Sites near you

Start Over

KZR Research Site

Thousand Oaks, CA United States
  Connect »

KZR Research Site

DeBary, FL United States
  Connect »

KZR Research Site

Miami, FL United States
  Connect »

KZR Research Site

Orlando, FL United States
  Connect »

KZR Research Site

Palm Harbor, FL United States
  Connect »

KZR Research Site

Tampa, FL United States
  Connect »

KZR Research Site

Winter Park, FL United States
  Connect »

KZR Research Site

Memphis, TN United States
  Connect »

KZR Research Site

Houston, TX United States
  Connect »

KZR Research Site

Upland, CA United States
  Connect »

KZR Research Site

Great Neck, NY United States
  Connect »

KZR Research Site

Manhasset, NY United States
  Connect »

KZR Research Site

Rochester, NY United States
  Connect »

KZR Research Site

Columbus, OH United States
  Connect »

KZR Research Site

Parkville, Australia
  Connect »

KZR Research Site

Bucaramanga, Colombia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.